Polymorphisms of tumor necrosis factor-α, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus

Clinica Chimica Acta

Volumn 383, Issue 1-2, 2007, Pages 133-139

  Li, Dan ^a   Zhu, Ji Ye ^a   Gao, Jie ^a   Wang, Xin ^a   Lou, Ya Qing ^a   Zhang, Guo Liang ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

CYP3A5; IL 10; Immunosuppressant therapy; Liver transplantation; Polymorphism; TNF

Indexed keywords

CYTOCHROME P450 3A5; INTERLEUKIN 10; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHINESE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34347354233     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.05.008     Document Type: Article

References (41)

1. Marshall S.E., Mclaren A.J., Mckinney E.F., et al. Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation 71 (2001) 469-476
2. Abdel-Razzak Z., Loyer P., Fautrel A., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44 (1993) 707-715
3. Gorski J.C., Hall S.D., Becker P., Affrime M.B., Cutler D.L., and Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 67 (2000) 32-43
4. Muntane-Relat J., Ourlin J.C., Domergue J., and Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22 (1995) 1143-1153
5. Mosmann T.R., and Moore K.W. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 12 (1991) A49-A53
6. Wilson A.G., Symons J.A., Mcdowell T.L., Mcdevitt H.O., and Duff A.G.W. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci U S A 94 (1997) 3195-3199
7. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 (1997) 1-8
8. Chang Y.T., Liu H.N., Yu C.W., et al. Cytokine gene polymorphisms in bullous pemphigoid in a Chinese population. Br J Dermatol 154 (2006) 79-84
9. Grove J., Daly A.K., Bassendine M.F., Gilvarry E., and Day C.P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46 (2000) 540-545
10. Jones D.E., Watt F.E., Grove J., et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol 30 (1999) 232-236
11. Bathgate A., Pravica V., Perrey C., et al. The effect of polymorphisms in tumor necrosis factor-[alpha], interleukin-10, and transforming growth factor-[beta] 1 genes in acute hepatic allograft rejection. Transplantation 69 (2000) 1514-1517
12. Fernandes H., Koneru B., Fernandes N., et al. Investigation of promoter polymorphisms in the tumor necrosis factor-a and interleukin-10 genes in liver transplant patients. Transplantation 73 (2002) 1886-1891
13. Warle M.C., Farhan A., Metselaar H.J., et al. Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transpl 8 (2002) 603-611
14. Mas V.R., Fisher R.A., Maluf D.G., et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet 65 (2004) 191-201
15. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43 (2004) 623-653
16. *1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14 (2004) 471-478
17. Yu S., Wu L., Jin J., et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81 (2006) 46-51
18. Sattler M., Guengerich F.P., Yun C.H., Christians U., and Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20 (1992) 753-761
19. Saeki T., Ueda K., Tanigawara Y., Hori R., and Komano T. Human P-glycoprotein transports cyclosporin A and FK-506. J Biol Chem 268 (1993) 6077-6080
20. Chen H.Y., Chen W.C., Hsu C.M., Tsai F.J., and Tsai C.H. Tumor necrosis factor a, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol 122 (2005) 73-78
21. van Schaik R.H.N., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48 (2002) 1668-1671
22. Tang K., Ngoi S.M., Gwee P.C., et al. Distinct haplotype profiles and strong linkage disequilibrium at the ABCB1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12 (2002) 437-450
23. Ameyaw M.M., Regateiro F., Li T., et al. ABCB1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11 (2001) 217-221
24. Agarwal P., Oldenburg M.C., Czarneski J.E., et al. Comparison study for identifying promoter allelic polymorphism in interleukin 10 and tumor necrosis factor a genes. Diagn Mol Pathol 9 (2000) 158-164
25. Warle M.C., Metselaar H.J., Hop W.C.J., and Tilanus H.W. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl 11 (2005) 19-26
26. Floyd M.D., Gervasini G., Masica A.L., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics 13 (2003) 595-606
27. He P., Court M.H., Greenblatt D.J., and Von Moltke L.L. Genotype-phenotype association of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77 (2005) 373-387
28. Wen S., Wang H., Ding Y., Liang H., and Wang S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet Test 8 (2004) 411-416
29. Huizinga T.W., Westendorp R.G., Bollen E.L., et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 72 (1997) 149-153
30. Duan S., Xu Y., Chen W., et al. No association between the promoter variants of tumor necrosis factor alpha (TNF-a) and schizophrenia in Chinese Han population. Neurosci Lett 366 (2004) 139-143
31. Kim Y.J., Lee H.S., Yoon J.H., et al. Association of TNF-a promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 12 (2003) 2541-2546
32. Cheong J.Y., Cho S.W., Hwang I.I.L., et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-a gene promoter polymorphisms. J Gastroenterol Hepatol 21 (2006) 1163-1169
33. Niro G.A., Fontana R., Gioffreda D., et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 25 (2005) 1175-1181
34. Xu X.W., Lu M.H., and Tan D.M. Association between tumour necrosis factor gene polymorphisms and the clinical types of patients with chronic hepatitis B virus infection. Clin Microbiol Infect 11 (2005) 52-56
35. Hohler T., Kruger A., Gerken G., Schneider P.M., Meyer Zum Buschenfelde K.H., and Rittner C. A tumor necrosis factor-alpha (TNF-a) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111 (1998) 579-582
36. Migita K., Miyazoe S., Maeda Y., et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-b1 polymorphisms and hepatocellular carcinoma. J Hepatol 42 (2005) 505-510
37. Tada H., Tsuchiya N., Satoh S., et al. Impact of CYP3A5 and ABCB1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37 (2005) 1730-1732
38. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and ABCB1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147-154
39. Mai I., Perloff E.S., Bauer S., et al. ABCB1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 58 (2004) 548-553
40. Wang W., Jin J., Zheng S., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 12 (2006) 775-780
41. Anglicheau D., Verstuyft C., Laurent-Puig P., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14 (2003) 1889-1896